› ‹
  • 1
  • 2

A Professional-Caliber Contract Research Organization with Top Academic Expertise

  • Clinical Coordination
  • Biostatistics & Data Management
  • Therapeutic Expertise
  • Clinical Coordinating Center (CCC)
  • Centralized CT Reading Center
  • Surgical Support Center
  • Investigator Selection & Qualification
  • Clinical Site Management
  • Safety & Pharmacovigilance
  • On-site and Remote QA Monitoring
  • Regulatory (IND, IDE, GCP)
  • Data Coordinating Center (DCC)
  • Clinical Data Management
  • Advanced Biostatistics
  • Adaptive Randomization
  • Electronic Data Capture (EDC)
  • Electronic Trial Master File (eTMF)
  • Clinical Trial Management System (CTMS)
  • Online Training & Certification
  • Hemorrhagic Stroke (ICH, IVH)
  • Ischemic Stroke, TIA
  • Global Ischemia
  • Traumatic Brain Injury (TBI)
  • Encephalitis
  • Functional & Cognitive Outcomes
  • Epilepsy
  • Neurosurgery
Log in Register

Login to your account

Username
Password *
Remember Me

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368

Our Latest Clinical Trials

  • All
  • Stroke
  • Epilepsy
  • Default
  • Title
  • Date
  • Random
  • Read More
    CLEAR-III is an international 500-patient randomized clinical trial evaluating thrombolysis vs. medical management alone in the treatment of intraventricular hemorrhage. With 75 hospitals participating, enrollment is expected to complete in late 2014.
    • Stroke
  • Read More
    MISTIE-III is a proposed 500-patient international multicenter clinical trial to confirm the safety and long-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH). The trial is under consideration for funding by NIH and is expected to start in mid-to-late 2013.
    • Stroke
  • Read More
    EQUIGEN is composed of two sister, bioequivalency trials. The EQUIGEN Chronic Dose trial is comparing two disparate generics of lamotrigine. The trial is being conducted at 6 sites, with each enrolling approximately 6 subjects each over 12 months. The EQUIGEN Single Dose trial is comparing brand lamotrigine with two disparate generics of lamotrigine. The trial is being conducted at 5 sites, with each enrolling approximately 11 subjects each over 12 months. The University of Cincinnati has contracted with the Johns Hopkins Brain Injury Outcomes team to serve as the Coordinating Center and the Kansas University Medical Center to serve as the Data Management Center for both trials.
    • Epilepsy
  • Read More
    MISTIE-II was a phase-II clinical trial across 32 clinical sites evaluating efficacy and long-term outcomes of thrombolysis in intracerebral hemorrhage (ICH). Results were presented at the 2013 International Stroke Conference.
    • Stroke
  • Read More
    ICES is the third tier in the MISTIE phase-II clinical trial. ICES is evaluating minimally-invasive endoscopic removal of the intracerebral hematoma as a faster alternative to catheter-delivered intermittent thrombolytic therapy. Enrollment is closed and the last patient should reach Day-365 in April-2013.
    • Stroke